Literature DB >> 1360270

The human hematopoietic stem cell in vitro and in vivo.

C J Eaves1, H J Sutherland, C Udomsakdi, P M Lansdorp, S J Szilvassy, C C Fraser, R K Humphries, M J Barnett, G L Phillips, A C Eaves.   

Abstract

A quantitative assay for a primitive human hematopoietic cell has been developed. The cell identified has been assigned the operational designation of long-term culture (LTC)-initiating cell based on its ability when cultured on supportive fibroblast monolayers to give rise to daughter cell(s) detectable by standard in vitro colony assays. Three lines of evidence support the view that the LTC-initiating cell assay may allow the relatively specific enumeration of totipotent cells with in vivo reconstituting potential. These involve the demonstration: (1) that conditions in analogous murine long-term cultures stimulate the extensive amplification (self-renewal) of some totipotent long-term repopulating cells, (2) that most of the LTC-initiating cells in normal human bone marrow are phenotypically different from most of the colony-forming cells present in the same cell suspensions in their possession of a number of characteristics specifically associated with transplantable stem cells; and (3) that cultured marrow cells from patients with chronic myeloid leukemia which, after maintenance under LTC conditions for 10 days contain some normal LTC-initiating cells but no detectable leukemic LTC-initiating cells, can after autografting reconstitute the hematopoietic system with normal cells.

Entities:  

Mesh:

Year:  1992        PMID: 1360270

Source DB:  PubMed          Journal:  Blood Cells        ISSN: 0340-4684


  8 in total

1.  Adult human circulating CD34⁻Lin⁻CD45⁻CD133⁻ cells can differentiate into hematopoietic and endothelial cells.

Authors:  Elisa Ciraci; Silvia Della Bella; Ombretta Salvucci; Cristina Rofani; Marta Segarra; Caterina Bason; Agnese Molinari; Dragan Maric; Giovanna Tosato; Anna C Berardi
Journal:  Blood       Date:  2011-06-29       Impact factor: 22.113

2.  Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.

Authors:  M Bhatia; J C Wang; U Kapp; D Bonnet; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

3.  Self-renewal of the long-term repopulating stem cell.

Authors:  G Brecher; N Bookstein; W Redfearn; E Necas; M G Pallavicini; E P Cronkite
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

Review 4.  Cell-based liver therapies: past, present and future.

Authors:  Valeria Iansante; Anil Chandrashekran; Anil Dhawan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

5.  Transfer and expression of the human multiple drug resistance gene as potential human gene therapy.

Authors:  A Bank; M Ward; C Richardson; P Pioli; C Hesdorffer
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

6.  Ex vivo expansion of primitive hematopoietic cells for cellular therapies: An overview.

Authors:  T A McAdams; C E Sandstrom; W M Miller; J G Bender; E T Papoutsakis
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

Review 7.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.

Authors:  R E Parchment
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

Review 8.  A Prospective Analysis of Human Leukemogenesis.

Authors:  Connie J Eaves
Journal:  Stem Cell Reports       Date:  2018-11-13       Impact factor: 7.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.